Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity

Chemotherapeutic agents are generally used as a frontline therapy for non-small cell lung cancer (NSCLC). However, resistance to chemotherapy arises rapidly in NSCLC, and the reasons for chemotherapy resistance have not been fully determined. Here, we found cisplatin, but not paclitaxel and doxorubi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cell Death Dis
Prif Awduron: Wang, Lihui, Liu, Xing, Ren, Yong, Zhang, Jingyuan, Chen, Junli, Zhou, Wenlong, Guo, Wei, Wang, Xiaoxuan, Chen, Huiping, Li, Meng, Yuan, Xiangzhong, Zhang, Xun, Yang, Jingyu, Wu, Chunfu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2017
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5477570/
https://ncbi.nlm.nih.gov/pubmed/28406482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2016.409
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg